Email this article Adipocytokine profile and effectiveness of the weight loss in patients with metabolically healthy obesity
- Authors: Romantsova T.I.1, Ostrovskaya E.V.1, Gerasimov A.N.1, Novoselova T.E.1, Novikova O.V.1, Valiulina D.S.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: Vol 46, No 3 (2018)
- Pages: 212-221
- Section: ARTICLES
- URL: https://almclinmed.ru/jour/article/view/823
- DOI: https://doi.org/10.18786/2072-0505-2018-46-3-212-221
- ID: 823
Cite item
Full Text
Abstract
Background: Obesity is a major risk factor for diabetes mellitus and cardiovascular diseases. Nevertheless, some obese patients have normal parameters of blood arterial pressure, carbohydrate, and lipid metabolism ("metabolically healthy obesity", MHO).
Aim: To study adipocytokine levels and to assess the effect of weight loss on cardiometabolic risk factors in patients with metabolically healthy obesity.
Materials and methods: We conducted a comparative analysis of the main metabolic parameters and adipocytokine levels in 44 female patients with MHO (according to the IDF criteria of the metabolic syndrome, 2005: obese patients with no more than one additional cardiometabolic risk factor) and in 33 women with metabolically unhealthy obesity (MUHO). We also assessed changes of these indices in the patients who reduced their body weight by ≥ 5% at 6 months.
Results: At baseline, body mass index (BMI) and the levels of basal insulin, C-reactive protein (CRP), tumor necrosis factor alfa (TNF-α), adiponectin and retinol-binding protein-4 (RBP-4) in the MHO and MUHO groups were comparable. A significant difference between these groups was observed for the HOMA index (3.0 and 4.4, respectively; p < 0.05), alanine aminotransferase (ALT) (23.49 and 37.39 U/l; p = 0.001), interleukin-6 (0.76 and 1.5 pg/ml; p < 0.05), chemerin (322.4 and 369.2 ng/ml; p < 0.05), and the duration of obesity (18 and 22.6 years; p < 0.05). At 6 months, in those MHO patients, who reduced body weight by ≥ 5% of the initial (66%), there was a significant increase of adiponectin by 4.54 ± 0.83 µg/ml (p < 0.05) and a reduction of waist circumference (WC) by -8.6 ± 1 cm (p > 0.05), НОМА index by -1.13 ± 0.42 (p < 0.05), CRP by -1.7 ± 0.4 mg/l (p < 0.05), RBP-4 by 2.9 ± 1.0 ng/ml (p < 0.05), and сhemerin by -46.6 ± 17.0 ng/ml (p < 0.05). In the MHO group, we found a positive correlation between changes in the adiponectin levels and the degree of reduction in body weight (p < 0.01), changes in RBP-4 and WC (p < 0.05), and changes in the levels of interleukin-6 and high-density lipoprotein (p < 0.05).
Conclusion: Compared to the complicated obesity, MHO is associated with a shorter disease history, and lower levels of the HOMA index, interleukin-6, and chemerin levels. The body mass decrease in MHO is associated with a decrease in the proinflammatory adipocytokine levels and of the HOMA index that determines the need for treatment of obesity, regardless of its phenotype.About the authors
T. I. Romantsova
I.M. Sechenov First Moscow State Medical University
Email: fake@neicon.ru
Tatiana I. Romantsova – MD, PhD, Professor, Department of Endocrinology, Faculty of Medicine.
8/2 Trubetskaya ul., Moscow, 119991
РоссияE. V. Ostrovskaya
I.M. Sechenov First Moscow State Medical University
Author for correspondence.
Email: e-ostrovsky@mail.ru
Elena V. Ostrovskaya – Postgraduate Student, Department of Endocrinology, Faculty of Medicine.
123–1–8 Leninskiy prospekt, Moscow, 117513, Tel.: +7 (909) 626 56 54 РоссияA. N. Gerasimov
I.M. Sechenov First Moscow State Medical University
Email: fake@neicon.ru
Andrey N. Gerasimov – Dr. Sci. in Physics and Mathematics, Professor, Head of the Chair of Medical Informatics and Statistics, Faculty of Preventive Medicine.
8/2 Trubetskaya ul., Moscow, 119991
РоссияT. E. Novoselova
I.M. Sechenov First Moscow State Medical University
Email: fake@neicon.ru
Tamara E. Novoselova – Senior Lecturer, Chair of Medical Informatics and Statistics, Faculty of Preventive Medicine.
8/2 Trubetskaya ul., Moscow, 119991
РоссияO. V. Novikova
I.M. Sechenov First Moscow State Medical University
Email: fake@neicon.ru
Oksana V. Novikova – MD, Doctor, Biochemical Laboratory, Centralized Laboratory Diagnostic Service of Laboratory Hemotransfusion Complex.
8/2 Trubetskaya ul., Moscow, 119991
РоссияD. S. Valiulina
I.M. Sechenov First Moscow State Medical University
Email: fake@neicon.ru
Dinar S. Valiulina – Biologist, Biochemical Laboratory, Centralized Laboratory Diagnostic Service of Laboratory Hemotransfusion Complex.
8/2 Trubetskaya ul., Moscow, 119991
РоссияReferences
- GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, Marczak L, Mokdad AH, Moradi-Lakeh M, Naghavi M, Salama JS, Vos T, Abate KH, Abbafati C, Ahmed MB, Al-Aly Z, Alkerwi A, Al-Raddadi R, Amare AT, Amberbir A, Amegah AK, Amini E, Amrock SM, Anjana RM, Ärnlöv J, Asayesh H, Banerjee A, Barac A, Baye E, Bennett DA, Beyene AS, Biadgilign S, Biryukov S, Bjertness E, Boneya DJ, Campos-Nonato I, Carrero JJ, Cecilio P, Cercy K, Ciobanu LG, Cornaby L, Damtew SA, Dandona L, Dandona R, Dharmaratne SD, Duncan BB, Eshrati B, Esteghamati A, Feigin VL, Fernandes JC, Fürst T, Gebrehiwot TT, Gold A, Gona PN, Goto A, Habtewold TD, Hadush KT, Hafezi-Nejad N, Hay SI, Horino M, Islami F, Kamal R, Kasaeian A, Katikireddi SV, Kengne AP, Kesavachandran CN, Khader YS, Khang YH, Khubchandani J, Kim D, Kim YJ, Kinfu Y, Kosen S, Ku T, Defo BK, Kumar GA, Larson HJ, Leinsalu M, Liang X, Lim SS, Liu P, Lopez AD, Lozano R, Majeed A, Malekzadeh R, Malta DC, Mazidi M, McAlinden C, McGarvey ST, Mengistu DT, Mensah GA, Mensink GBM, Mezgebe HB, Mirrakhimov EM, Mueller UO, Noubiap JJ, Obermeyer CM, Ogbo FA, Owolabi MO, Patton GC, Pourmalek F, Qorbani M, Rafay A, Rai RK, Ranabhat CL, Reinig N, Safiri S, Salomon JA, Sanabria JR, Santos IS, Sartorius B, Sawhney M, Schmidhuber J, Schutte AE, Schmidt MI, Sepanlou SG, Shamsizadeh M, Sheikhbahaei S, Shin MJ, Shiri R, Shiue I, Roba HS, Silva DAS, Silverberg JI, Singh JA, Stranges S, Swaminathan S, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tegegne BS, Terkawi AS, Thakur JS, Tonelli M, Topor-Madry R, Tyrovolas S, Ukwaja KN, Uthman OA, Vaezghasemi M, Vasankari T, Vlassov VV, Vollset SE, Weiderpass E, Werdecker A, Wesana J, Westerman R, Yano Y, Yonemoto N, Yonga G, Zaidi Z, Zenebe ZM, Zipkin B, Murray CJL. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377(1): 13–27. doi: 10.1056/NEJMoa1614362.
- Nichols GA, Horberg M, Koebnick C, Young DR, Waitzfelder B, Sherwood NE, Daley MF, Ferrara A. Cardiometabolic Risk Factors Among 1.3 Million Adults With Overweight or Obesity, but Not Diabetes, in 10 Geographically Diverse Regions of the United States, 2012–2013. Prev Chronic Dis. 2017;14:E22. doi: 10.5888/ pcd14.160438.
- Alam I, Ng TP, Larbi A. Does inflammation determine whether obesity is metabolically healthy or unhealthy? The aging perspective. Mediators Inflamm. 2012;2012:456456. doi: 10.1155/2012/456456.
- Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocr Metab Disord. 2013;14(3): 219–27. doi: 10.1007/s11154-013-9252-x.
- Muniandy M, Heinonen S, Yki-Järvinen H, Hakkarainen A, Lundbom J, Lundbom N, Kaprio J, Rissanen A, Ollikainen M, Pietiläinen KH. Gene expression profile of subcutaneous adipose tissue in BMI-discordant monozygotic twin pairs unravels molecular and clinical changes associated with sub-types of obesity. Int J Obes (Lond). 2017;41(8): 1176–84. doi: 10.1038/ijo.2017.95.
- Alfadda A, Masood A, Al-Naami MY, Chaurand P, Benabdelkamel H. A Proteomics Based Approach Reveals Differential Regulation of Visceral Adipose Tissue Proteins between Metabolically Healthy and Unhealthy Obese Patients. Mol Cells. 2017;40(9): 685–95. doi: 10.14348/molcells.2017.0073.
- Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, Zhang BB, Bonaldo P, Chua S, Scherer PE. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol. 2009;29(6): 1575–91. doi: 10.1128/MCB.01300-08.
- Primeau V, Coderre L, Karelis AD, Brochu M, Lavoie ME, Messier V, Sladek R, Rabasa-Lhoret R. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond). 2011;35(7): 971–81. doi: 10.1038/ijo.2010.216.
- Badoud F, Perreault M, Zulyniak MA, Mutch DM. Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals. FASEB J. 2015;29(3): 748–58. doi: 10.1096/fj.14-263913.
- Khan UI, Ogorodnikova AD, Xu L, Wang D, Wassertheil-Smoller S, Ho GY, Sowers MF, Rajpathak SN, Allison MA, Mackey RH, Vitolins MZ, Manson JE, Wildman RP. The adipokine profile of metabolically benign obese and atrisk normal weight postmenopausal women: the Women's Health Initiative Observational Study. Obesity (Silver Spring). 2014;22(3): 786– 94. doi: 10.1002/oby.20139.
- Antoniades C. 'Dysfunctional' adipose tissue in cardiovascular disease: a reprogrammable target or an innocent bystander? Cardiovasc Res. 2017;113(9): 997–8. doi: 10.1093/cvr/cvx116.
- Janiszewski PM, Ross R. Effects of weight loss among metabolically healthy obese men and women. Diabetes Care. 2010;33(9): 1957–9. doi: 10.2337/dc10-0547.
- Sesti G, Folli F, Perego L, Hribal ML, Pontiroli AE. Effects of weight loss in metabolically healthy obese subjects after laparoscopic adjustable gastric banding and hypocaloric diet. PLoS One. 2011;6(3):e17737. doi: 10.1371/journal.pone.0017737.
- Dalzill C, Nigam A, Juneau M, Guilbeault V, Latour E, Mauriège P, Gayda M. Intensive lifestyle intervention improves cardiometabolic and exercise parameters in metabolically healthy obese and metabolically unhealthy obese individuals. Can J Cardiol. 2014;30(4): 434–40. doi: 10.1016/j.cjca.2013.11.033.
- Kantartzis K, Machann J, Schick F, Rittig K, Machicao F, Fritsche A, Häring HU, Stefan N. Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia. 2011;54(4): 864–8. doi: 10.1007/s00125-010-2006-3.
- Arsenault BJ, Côté M, Cartier A, Lemieux I, Després JP, Ross R, Earnest CP, Blair SN, Church TS. Effect of exercise training on cardiometabolic risk markers among sedentary, but metabolically healthy overweight or obese post-menopausal women with elevated blood pressure. Atherosclerosis. 2009;207(2): 530–3. doi: 10.1016/j.atherosclerosis.2009.05.009.
- Karelis AD, Messier V, Brochu M, Rabasa-Lhoret R. Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia. 2008;51(9): 1752–4. doi: 10.1007/s00125008-1038-4.
- Andrade-Oliveira V, Câmara NO, Moraes-Vieira PM. Adipokines as drug targets in diabetes and underlying disturbances. J Diabetes Res. 2015;2015:681612. doi: 10.1155/2015/681612.
- Jeppesen J, Hansen TW, Olsen MH, Rasmussen S, Ibsen H, Torp-Pedersen C, Hildebrandt PR, Madsbad S. C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study. Eur J Cardiovasc Prev Rehabil. 2008;15(5): 594–8. doi: 10.1097/HJR.0b013e328308bb8b.
- Mauer J, Denson JL, Brüning JC. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 2015;36(2): 92–101. doi: 10.1016/j.it.2014.12.008.
- Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci. 2015;36(7): 461–70. doi: 10.1016/j.tips.2015.04.014.
- Берштейн ЛМ, Порошина ТЕ, Васильев ДА. Адипокины, миокины и цитокины при раке эндометрия: связь с фенотипом избыточной массы тела и клинико-морфологическими особенностями опухоли. Ожирение и метаболизм. 2017;14(1): 35–40. doi: 10.14341/ОМЕТ2017135-40.
- Mariani F, Roncucci L. Chemerin/chemR23 axis in inflammation onset and resolution. Inflamm Res. 2015;64(2): 85–95. doi: 10.1007/s00011014-0792-7.
- Phillips CM, Dillon C, Harrington JM, McCarthy VJ, Kearney PM, Fitzgerald AP, Perry IJ. Defining metabolically healthy obesity: role of dietary and lifestyle factors. PLoS One. 2013;8(10):e76188. doi: 10.1371/journal.pone.0076188.
Supplementary files
